Publicacións (76) Publicacións de José Ramón Yuste Ara

2024

  1. A Focus on the Pathophysiology of Adrenomedullin Expression: Endothelitis and Organ Damage in Severe Viral and Bacterial Infections

    Cells, Vol. 13, Núm. 11

  2. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

2023

  1. Clinical Impact of Rapid Bacterial Microbiological Identification with the MALDI-TOF MS

    Antibiotics, Vol. 12, Núm. 12

  2. Mid-Regional Pro-Adrenomedullin Can Predict Organ Failure and Prognosis in Sepsis?

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

2022

  1. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d

    Frontiers in Immunology, Vol. 13

  2. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 74, Núm. 5, pp. 757-765

  3. Impact of Infectious Diseases training in the perception of antibiotic resistance and rational use of antibiotics among Spanish medical students – a cross-sectional study

    BMC Medical Education, Vol. 22, Núm. 1

  4. Impact of the Acceptance of the Recommendations Made by a Meropenem Stewardship Program in a University Hospital: A Pilot Study

    Antibiotics, Vol. 11, Núm. 3

  5. Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 2, pp. 295-299

2021

  1. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

    Journal of Clinical Investigation, Vol. 131, Núm. 20

  2. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?

    Journal of Internal Medicine, Vol. 289, Núm. 1, pp. 116-120

  3. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  4. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

    Frontiers in Immunology, Vol. 12

  5. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge

    Frontiers in Immunology, Vol. 12

  6. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

  7. Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation

    The Journal of infectious diseases, Vol. 223, Núm. 7, pp. 1205-1213

  8. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

    EClinicalMedicine, Vol. 32

2020

  1. Safety and Tolerability of More than Six Days of Tedizolid Treatment

    Antimicrobial agents and chemotherapy, Vol. 64, Núm. 7

  2. The sars-cov-2 ivermectin navarra-isglobal trial (saint) to evaluate the potential of ivermectin to reduce covid-19 transmission in low risk, non-severe covid-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

    Trials, Vol. 21, Núm. 1

2019

  1. Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients

    Antiviral Therapy, Vol. 24, Núm. 4, pp. 313-319